ESKAPE group (Table 1). All 6 pathogens of ESKAPE category were isolated from animals in association with one or other disease conditions. Of those, most of the isolates belonged to Enterobacter species (44.4%) followed by Klebsiella pneumoniae (22.1%), Pseudomonas aeruginosa (16.6%), Staphylococcu specimens, out of which n = 4974 (72.22%) were ESKAPE pathogens. Overall, as shown in Table1, we observed the dominance of Gram-negative bacteria. The Enterobacterales group was predominant. Antibiotics 2020, 9, 624 3 of 17 among all ESKAPE isolates, with 75% of all isolates being from this group. Escherichia coli was the mos The ESKAPE Pathogens are: Enterococcus faecium Enterococcus faecium; formerly known as Streptococcus faecium until its re-categorization in 1984, is a human pathogen that causes nosocomial bacteremia, surgical wound infection, endocarditis, and urinary tract infections. The bacteria can survive for long period antibiotics, the WHO published its list of pathogens for which new antimicrobial developmentisurgentlyneeded.Withinthisbroadlist,ESKAPE(Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa,andEnterobacter species)pathogens(11)weredesignatedprioritystatus (12)
ESKAPE pathogens Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumanii, Pseudomonas aeruginosa, and Enterobacter species are currently the cause of majority of hospital infections globally and they also . Download Full PDF Package. This paper were ESKAPE pathogens and 891(29.72%) were non ESKAPE pathogens. Among the ESKAPE pathogens, the most prevalent microorganism isolated was Staphylococcus aureus 19.17% (575), followed by Klebsiella pneumoniae 16.14% (484), Pseudomonas aeruginosa 10.97% (329), Acinetobacter species 9.67%(290), Enterococcus specie
.) - acronymically dubbed 'the ESKAPE pathogens' - capable of 'escaping' the biocidal action of antibiotics and mutually representing new. Antimicrobial-resistant ESKAPE (E nterococcus faecium, S taphylococcus aureus, K lebsiella pneumoniae, A cinetobacter baumannii, P seudomonas aeruginosa, and E nterobacter species) pathogens represent a global threat to human health.The acquisition of antimicrobial resistance genes by ESKAPE pathogens has reduced the treatment options for serious infections, increased the burden of disease. ESKAPE PATHOGENS PDF. Literature ESKAPE PATHOGENS PDF admin March 14, 2020 no Comments . This review consolidates clinically relevant information on the background and management of the ESKAPE pathogens. Bad Bugs, No Drugs: No ESKAPE!. pathogens, such as MRSA, few novel molecules have been advanced for treatment of the other ESKAPE pathogens.
ESKAPE PATHOGENS PDF. admin. Relationship | June 28, 2019. This review consolidates clinically relevant information on the background and management of the ESKAPE pathogens. Bad Bugs, No Drugs: No ESKAPE!. pathogens, such as MRSA, few novel molecules have been advanced for treatment of the other ESKAPE pathogens. Dec 11, The biggest concern. We found that ESKAPE pathogens represented 42.2% of species isolated from bloodstream infections and, compared with non-ESKAPE pathogens, were associated with a 3.3-day increase in length of stay, a $5500 increase in cost of care, and a 2.1% absolute increase in mortality (P < 1e-99).ESKAPE pathogens were not universally more resistant to antibiotics, but only to select antibiotics (P < 5e-6. ESKAPE is an acronym comprising the scientific names of six highly virulent and antibiotic resistant bacterial pathogens including: Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter spp. This group of Gram-positive and Gram-negative bacteria can evade or 'escape' commonly used antibiotics due to their.
2019 AR Threats Report. CDC's Antibiotic Resistance Threats in the United States, 2019 (2019 AR Threats Report) includes the latest national death and infection estimates that underscore the continued threat of antibiotic resistance in the U.S.. According to the report, more than 2.8 million antibiotic-resistant infections occur in the U.S. each year, and more than 35,000 people die as a result WHO publishes list of bacteria for which new antibiotics are urgently needed. WHO today published its first ever list of antibiotic-resistant priority pathogens - a catalogue of 12 families of bacteria that pose the greatest threat to human health. The list was drawn up in a bid to guide and promote research and development (R&D) of new.
The acronym ESKAPE includes six nosocomial pathogens that exhibit multidrug resistance and virulence: Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter spp. Persistent use of antibiotics has provoked the emergence of multidrug resistant (MDR) and extensively drug resistant (XDR) bacteria, which render even the. The identification of bacterial pathogens is the critical first step in conquering infection diseases. A novel turn-on fluorescent probe for the selective sensing of nitroreductase (NTR) activity and its initial applications in rapid, real-time detection and identification of ESKAPE pathogens have been reported Background. Infections caused by antibiotic-resistant bacteria continue to challenge physicians in 2008. We face growing resistance among gram-positive and gram-negative pathogens that cause infection in the hospital and in the community .Rice  recently reported these as the ESKAPE pathogens Enterococcus faecium,Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumanii. The ESKAPE pathogen group represents the leading cause of these infections, and upregulation of efflux pump expression is a significant mechanism of resistance in these pathogens. This has resulted in substantial interest in the development of efflux pump inhibitors to combat antibiotic-resistant infections; however, no widespread treatments. by ESKAPE pathogens can lead to death of the patient and a spread of multi-resistant strains. Antibacterial resistance has now been detected for nearly all new antibiotics, even those of last resort (Jelic et al.,2017;Li and Webster, 2018). As a consequence, the WHO have created an urgen
incidence of infections due to ESKAPE pathogens, site-by-site surveillance studies and antibiograms are necessary to inform effective empiric therapy.8 This study assessed trends in annual resistance rates for all ESKAPE pathogens processed over a five-year period from 2011 through to 2015 in KwaZulu-Natal, South Africa. Evidence before this stud Studies show that ESKAPE pathogens ment of centralized labs for high-throughput analysis of clinical are responsible for over 40% of infections in patients in intensive samples. care units . The assays in most modern instruments for bacterial identifi- There are two measurable factors that can guide the treatment cation are based on well. ESKAPE. The above mentioned pathogens are responsible for lethal in-fections amongst critically ill and immunocompromised individuals as a result of lack of treatment . Thus the consequences of ESKAPE could be devastating. 2.1. Enterococcus faecium (E. faecium) E. faecium is a Gram-positive spherical (cocci) bacterium that occur
This process resulted in a mass spectral ESKAPE pathogen library of six unique species and an additional 44 non-ESKAPE pathogens used as decoys for further analyses (Supplementary Table S2). Figure pathogens cause nearly half the infections that were caused by bacteria and the most common ESKAPE pathogen was Klebsiella pneumonia,followed by Pseudomonas aeruginosa. Enterococcus faecium, Enter-obacter. Pseudomonas aeruginosa and Klebsiella pneumoniawere multidrug resistant
Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J Infect Dis. 2008;197(8):1079-81. Boucher HW et al. Bad Bugs, No Drugs: No ESKAPE The importance of ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species) to the establishment and promotion of antimicrobial resistance in hospitalized patients was first recognized in a 2008 publication by Rice. 1 The morbidity and mortality associated with Gram-negative ESKAPE pathogens. the acronym ESKAPE by Infectious Disease Society of America for their propensity to escape biocidal action of antibiotics (Rice 2008; Pendleton et al. 2013). More importantly, the entire spectrum of ESKAPE pathogens falls under critical and high priority category among the list of 12 priority pathogens released by WHO. ESKAPE pathogens Antibiotic resistance (ABR) is one of the biggest threats to global health. Infections by ESKAPE (Enterococcus, S. aureus, K. pneumoniae, A. baumannii, P. aeruginosa, and E. coli) organisms are the leading cause of healthcare-acquired infections worldwide. ABR in ESKAPE organisms is usually associated with significant higher morbidity, mortality, as well as economic burden Inactivation of various ESKAPE pathogens in a nutrious media as a function of time. Note that 5 of the 6 organisms show a greater than 90% reduction after 6 hours of exposure to an irradiance typically found in a clinical setting. While these measurements are instructive, they do not represent the full range of clinical conditions than an.
Distribution of ESKAPE Pathogens Among the Diverse Clinical Specimens. Among the different clinical specimens processed, ESKAPE pathogens were most commonly isolated from urine specimens followed by pus, sputum and other bodily fluids ().Considering gender, 249 (55.1%) ESKAPE pathogens were isolated from females and 203 (44.9%) from males REVIEW Open Access Economic burden of antibiotic resistance in ESKAPE organisms: a systematic review Xuemei Zhen1,2, Cecilia Stålsby Lundborg2, Xueshan Sun1, Xiaoqian Hu1 and Hengjin Dong1,3* Abstract Background: Antibiotic resistance (ABR) is one of the biggest threats to global health The past decade has brought a significant rise in antimicrobial resistance, and the ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter species) have considerably aggravated a threat to public health, causing nosocomial infections worldwide. The objective of the current study was to isolate novel. Such pathogens tend to 'escape' from the traditional marketed antimicrobial inhibitory action. 5, 6 The acronym ESKAPE was used for the first time in 2008 to name a group of pathogens where Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii , Pseudomonas aeruginosa e Enterobacter spp. 5 were part of it
K. fedtschenkoi Against ESKAPE Pathogens Nicholas Richwagen, Emory University James T. Lyles, Emory University Brandon L. F. Dale, Emory University Cassandra Quave, Emory University Journal Title: Frontiers in Pharmacology Volume: Volume 10 Publisher: Frontiers Media | 2019-02-06, Pages 67-67 Type of Work: Article | Final Publisher PDF Presence of ESKAPE pathogens in foodstuffs is alarming and considers threatening public health. Pathogen identification using MALDI-TOF will provide an effective tool to identify the causes of foodborne illness and allow the physicians to apply rapid and effective antimicrobials in an optimized time to the patient The prevalence of healthcare-acquired infections (HAI) and rising levels of antimicrobial resistance places significant economic and public health burdens on modern healthcare systems. A group of highly drug resistant pathogens known as the ESKAPE pathogens, along with C. difficile, are the leading causes of HAIs. Interactions between patients, healthcare workers, and environmental conditions. Results. In a 6 month period, ESKAPE pathogens were isolated from non-duplicate blood cultures in 81 episodes of 72 cases of pediatric cancer patients, while CoNS were isolated from 135 blood cultures of 116 patients.The ESKAPE pathogens isolated were Enterobacter spp., methicillin-resistant Staphylococcus aureus (MRSA), Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa. Abstract <p>ESKAPE bacteria are a major cause of multidrug-resistant infections, and new drugs are urgently needed to combat these pathogens. Given the importance of iron in bacterial physiology and pathogenicity, iron uptake and metabolism have become attractive targets for the development of new antibacterial drugs
This study used 12 strains from six bacterial species recognized as ESKAPE pathogens, including Gram-negative [Klebsiella pneumoniae (CDC-004), Acinetobacter baumannii (CDC-0033), Pseudomonas. ESKAPE Pathogens and their Safe Relatives There are six organisms that are currently considered to be major threats, not because they can cause the most devastating illnesses, but because the infections they do cause are often very difficult to treat. A majority of the antibiotic-resistant infections that occur in healthcare settings are caused by one of these six bacteria, collectively known. First, across a dataset of more than 400,000 patients, we found bacteremia caused by ESKAPE pathogens was associated with a 3.3-day increase in length of hospital stay, a $5,500 increase in the.
Molecular Epidemiology of Antibiotic Resistant ESKAPE Pathogens Isolated from Public Sector Hospitals in uMgungundlovu District, Kwazulu-Natal, South Africa Raspail Carrel Founou Zangue 216 076 503 A thesis submitted to the School of Laboratory Medicine and Medical Sciences, College of Healt potential of NAI-107 for treating serious ESKAPE pathogens: synergistic combinations against Gram-negatives and bactericidal activity against non-dividing cells. The Journal of antimicrobial chemotherapy, 73(2), 414-424 pathogens. USF inventors have developed a series of novel Hsp90 inhibitors that they have shown to be effective against Leishmania donovani and ESKAPE pathogens. This development has the potential to provide a new more effective treatment that is also less toxic than the current gold standard treatments. Tech ID # 15A051 Patent #: 9,737,50 The ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species) are the leading cause of nosocomial infections throughout the world. Most of them are multidrug resistant isolates, which is one of the greatest challenges in clinical practice
Efficacy Claims section] including ESKAPE pathogens - Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumonia, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter aerogenes (This product) (Oxivir Tb) [ insert marketed product name] kills ESKAPE organisms with a 1 minute kill time Background ESKAPE is an acronym for a group of life-threatening nosocomial pathogens, viz, Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter spp. Global efforts on controlling multidrug-resistant (MDR) organisms have been hampered by their ability to escape antibacterial drugs resistant (XDR) pathogens . The pneumonic, ESKAPE, was originally described by Rice  to designate the most challenging nosocomial pathogens with significant antibacterial resistance. It included the gram-positive pathogens, Enterococcus faecium . and . Staphylococcus aureus, as well as the gram-negative pathogens, Klebsiell
Acinetobacter baumannii is a clinically relevant pathogen which causes multi-drug resistant, hospital-acquired infections and is a top priority target for antibiotic development. Cryo -EM structures of the A. baumannii F1Fo-ATP synthase in three conformational states reveal unique features, which represent attractive sites for the development of novel therapeutics ESKAPE group describes pathogens responsible for hos-pital infections, which are most difﬁcult to treat. However, E. coli causing bacteremia infections and sepsis showed increasing resistance to ﬂuoroquinolones . The spread of resistance among pathogens is becoming a serious problem , and therefore searching for alternative drugs clik on the image and visit the new site. New site clik on the image. In silic
pathogens that belong to the so-called ESKAPE panel. ESKAPE is an abbreviation for the names of bacterial species most often developing resistance to antibiotics: Enterococcus faecium negative ESKAPE pathogens?3 Expected activity against CDC urgent or WHO critical threat pathogen?4 Potential indication(s)?5 Vabomere (meropenem + vaborbactam) Approved Aug. 30, 2017 (U.S. FDA) Melinta Therapeutics Inc. (formerly The Medicines Co.) β-lactam (carbapenem) + β-lactamase inhibitor (cyclic boronate)11,13 PBP, β-lactamase Yes Yes.
Medical Community'' . Studies show that ESKAPE pathogens are responsible for over 40% of infections in patients in intensive care units . There are two measurable factors that can guide the treatment of patients with bacterial infections. One factor is the minimum inhibitory concentration (MIC) of an antibiotic against the pathogen The ESKAPE pathogens (E. faecium, S. aureus, K. pneumoniae, A. baumannii, P. aeruginosa, and Enterobacter species) are a notorious group of deadly pathogens known to be the leading cause of hospital infections worldwide. Moreover, most of these ESKAPE pathogens have now develope The ESKAPE pathogens and NP • Nosocomial infections are commonly caused by the ESKAPE pathogens 1 • The ESKAPE pathogens were frequently isolated in a recent study of patients with VAP (particularly S. aureus)2 E S K A P E Enterococcus faecium Staphylococcus aureus Klebsiella pneumoniae Acinetobacter baumannii Pseudomonas aeruginosa. ESKAPE Pathogens and Effects on Biofilm Formation Tafadzwa Chipenzi,1 Genuine Baloyi,1 Tatenda Mudondo,1 Simbarashe Sithole ,2 Godloves Fru Chi,3 and Stanley Mukanganyama 2 1SchoolofPharmacy,CollegeofHealthSciences,UniversityofZimbabwe,Mt.Pleasant,Harare,Zimbabwe 2DepartmentofBiochemistry,UniversityofZimbabwe,Mt.Pleasant,Harare,Zimbabw
ESKAPE pathogens (E. faecium, S. aureus, K. pneumoniae, A. baumannii, P. aeruginosa, E. cloa-cae) are recognized to be responsible for the majority of difficult-to-treat community-acquired , healthcare-associated, and nosocomial infections . Multidrug-resistant bacteria represen the ESKAPE pathogens, which are capable of escaping the biocidal action of antibiotics and mutually representing new paradigms in pathogenesis, transmission and resistance . Several studies have analyzed the function of TAp systems in stabilizing the plasmids that carry resistance genes in clinical pathogens To Escape or Not to Eskape O. ur title's play on ter-minology is deliberate. ESKAPE when cap - italized, is the acro-nym given by clinical mi- crobiologists and in- fectious disease physicians to the coterie of resistant microbes better known as . Enterococcus faecium, Staphy-lococcus aureus, Klebsiella pneumoniae, Acinetobacte ESKAPE pathogens. To do this, we investigated the sequences of those rescue factors using a combination of . in silico. methods114 including keyword searches, similarity detection, protein domain prediction,115 ortholog clustering, and synteny analysis. This pipeline was applied to the . 116
Herbal Bioactives: An Escape to ESKAPE Pathogens: 10.4018/978-1-7998-2094-9.ch010: Infection is caused in the human body due to the invasion of pathogenic microbes, their multiplication, and production of toxins. The ESKAPE pathogen in 99,000 deaths due to antibacterial-resistant pathogens. qThe acronym ESKAPE includes six nosocomial pathogens that exhibit multidrug resistance (Enterococcus faecium,Staphylococcus aureus,Klebsiella pneumoniae,Acinetobacter baumannii,Pseudomonas aeruginosa, and several species ofEnterobacter)
ESKAPE pathogens - Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter species - is a recent designation proposed in the literature to include the most prevalent pathogens in hospitals . Enterococcus faecalis and Escherichia coli are also prevalent. All these. ESKAPE pathogens were first identified by the Infectious Diseases Society of America (IDSA) in 2004 (3, 20). Recently S. maltophila has become more prevalent, leading to ALS Environmental producing a specific suite of analysis for the IDSA pathogens plus S. maltophila (4, 5), referred to as ESKAPES pathogens: ESKAPES Pathogen General Descriptio S1 Supplementary data Real Time Detection of ESKAPE Pathogens by a Nitroreductase- triggered Fluorescence Turn-on Probe Shengnan Xu,a Qinghua Wang,ab Qingyang Zhang,ab Leilei Zhang,b Limin Zuo,c Jian- Dong Jiangac and Hai-Yu Hu*ab aState Key Laboratory of Bioactive Substances and Function of Natural Medicine, Institute of Materia Medica, Peking Union Medical College and Chinese Academy o First published on 18th September 2017. The identification of bacterial pathogens is the critical first step in conquering infection diseases. A novel turn-on fluorescent probe for the selective sensing of nitroreductase (NTR) activity and its initial applications in rapid, real-time detection and identification of ESKAPE pathogens have been reported
Introduction. The global increase in multi-resistant ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species) has created an urgent need to develop replacement therapies.ESKAPE pathogens are responsible for the top 6 health care-associated infections (HAIs) and many have been identified as. ESKAPE pathogens, that new antibacterials are urgently needed to treat). The ESKAPE pathogens account for over two-million infections and have healthcare costs upwards of $20 billion dollars annually. Over the past several decades, pharmaceutical companies have drastically reduced their research programs for developing new antibacterial agents
acronymically dubbed 'the ESKAPE pathogens' - capable of 'escaping' the biocidal action of antibiotics and mutually representing new paradigms in pathogenesis, transmission and resistance. European Suspension Test protocol. Enterococcus faecium Staphylococcus aureus Klebsiella pneumoniae (NOT INCLUDED ABOVE - IntY) Acinetobacter baumanni Healthcare institutions have seen an increase in infections caused by antibiotic-resistant ESKAPE pathogens. Current antibiotics have become less potent against pathogenic bacteria due to their overuse and misuse. In recent years, scientists have revisited local environments in search of novel antibioticproducing microbes to address the increasing threat of resistance
View Escape Pathogens and Safe Relatives Presentation.pptx from BIOLOGY MISC at Henderson State University. ESKAPE PATHOGENS AND SAFE RELATIVES TABLE D1: PAYTON KEHNER, SHYLA HULL, KALEE NEWSOM, AN 1. The research reported in this thesis, except where otherwise indicated is my original research. 2. This thesis has not previously been submitted for any qualification or exami In addition, simple word group algorithms predicted ESKAPE pathogens with a positive predictive value of 7.9% to 56.2%, exceeding 4.8% by random guessing (P<1e-99). Conclusion Figure 3: Schematic representation of a cystic fibrosis lung (A) and dental plaque (B). (A) In a healthy lung, the epithelial cells of the airway are covered with a thin layer of mucus whereas the airway of a CF lung contains a thick, sticky mucus including bacterial biofilms leading to damaging of the cells and breathing problems Download Full Article PDF. The aim of our study was to characterize the antimicrobial resistance in ESKAPE pathogens (E. faecium, S. aureus, Klebsiella spp., A. baumannii, P. aeruginosa and Enterobacter spp.) isolated from 606 culture-positive pneumonia: community-acquired (CAP), healthcare-associated (HCAP), hospital-acquired and ventilator.
ESKAPE pathogens are responsible for 42.2% of blood infections, 2. around 50 million infections each year, resulting in one in five deaths in the community or in onethree deaths in hospitals. 3. and are associated with higher lengths of stay, cost of care, and mortality compared with non-ESKAPE pathogens. 2 An overview of resistance profiles ESKAPE pathogens from 2010-2015 in a tertiary respiratory center in Romania. Nicolae Ovidiu Peneş, Andrei Alexandru Muntean, Adriana Moisoiu, Mădălina Maria Muntean, Alexandru Chirca, Miron Alexandru Bogdan, Mircea Ioan Popa Romanian Journal of Morphology and Embryology 2017, 58 (3): 909-92 The ESKAPE pathogens are responsible for the majority of recalcitrant bacterial outbreaks in nosocomial set-tings, but the therapeutic choices are extremely limited. Despite intensive searches for new antimicrobial agents, there are few ac-tive candidates in the pipeline. Here, we show the bactericida
Background The rapid increase in antibiotic resistance by various bacterial pathogens underlies the significance of developing new therapies and exploring different drug targets. A fraction of bacterial pathogens abbreviated as ESKAPE by the European Center for Disease Prevention and Control have been considered a major threat due to the rise in nosocomial infections ESKAPE pathogens, namely, Enterococcus faecium , Staphylococcus aureus , Klebsiella pneumoniae , Acinetobacter baumannii , Pseudomonas aeruginosa, and Enterobacter species, are responsible for a majority of all healthcare-acquired infections (HAI). The bacteria cause nosocomial infections in immunocompromised patients Finally, for 30-day MV-free days, VAP caused by resistant ESKAPE pathogens was significantly higher (5 days) than nonresistant ESKAPE pathogens or non-ESKAPE organisms . Discussion To our knowledge, this study is the first to report that strategies favoring homogeneity promote the rise and spread of VAP due ESKAPE microorganisms The joint research focuses on expanded studies on the mechanism of action of the new class of antibiotics against Gram-negative ESKAPE pathogens. The project started in January 2016 and was supervised jointly by Prof. John A. Robinson and Dr. Daniel Obrecht and has successfully completed in July 2018 Specifically, ESKAPE pathogens are the primary cause of nosocomial infections, which wreak morbidity and mortality in immune-compromised patients, with a potential threat of antibiotic resistance. Consequently, there is an ever-increasing impetus to discover newer inhibitors of these pathogenic strains Title:In Vitro Screening of an FDA-Approved Library Against ESKAPE Pathogens VOLUME: 23 ISSUE: 14 Author(s):Waleed Younis, Ahmed AbdelKhalek, Abdelrahman S. Mayhoub and Mohamed N. Seleem* Affiliation:Department of Comparative Pathobiology, Purdue University College of Veterinary Medicine, West Lafayette, IN 47906, Department of Comparative Pathobiology, Purdue University College of Veterinary.